The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma

Table 1 Relationship between PSMD14 expression level and clinicopathological features in 76 patients with osteosarcoma

Clinicopathological features	Number	PSMD14 expression		P value
Clinicopathological features	Number	High expression (n = 51)	Low expression (n = 25)	P value
Gender
Female	32	23	9
Male	44	28	16	0.450
Age (years)
< 18	48	30	16	0.664
≥ 18	28	21	9
Tumor site
Limbs	66	44	22	0.577
Others^a	10	7	3
Pathological subtype
Classical	68	46	22	0.769
Others^b	8	5	3
Pathological fracture
Yes	10	5	5	0.219
No	66	46	20
Operation
Amputation	15	8	7	0.205
Limb salvage	61	43	18
Pathological grade
High	65	48	17	0.004*
Moderate/low	11	3	8
Enneking stage
IIA/IIB	55	32	23	0.007*
III	21	19	2

^aSpine, pelvis, skull, scapula, etc.
^bPeriosteal osteosarcoma, paracortical osteosarcoma, telangiectatic osteosarcoma
*Fisher exact test

ISSN: 1475-2867